EMA Withdrawn: Taxespira (previously Docetaxel Hospira UK Limited ) (docetaxel trihydrate) — Hospira UK Limited

View source ↗

Summary

The EMA withdrew Taxespira (docetaxel trihydrate) from the market for multiple cancer indications including stomach, prostate, breast, head and neck cancers, an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Carcinoma Non-small-cell Lung
• Head and Neck Neoplasms
• Prostatic Neoplasms
• Stomach Neoplasms

Drugs mentioned

• Taxespira (docetaxel trihydrate)

Snippet

Status: Withdrawn. Therapeutic area: Stomach Neoplasms;Prostatic Neoplasms;Breast Neoplasms;Head and Neck Neoplasms;Carcinoma, Non-Small-Cell Lung. MAH: Hospira UK Limited. Decision date: 30/10/2018